300122 智飞生物
已收盘 07-22 15:00:00
资讯
新帖
简况
智飞生物(300122)7月17日主力资金净买入6411.91万元
证券之星 · 07-18
智飞生物(300122)7月17日主力资金净买入6411.91万元
智飞生物:截至2024年7月10日,公司普通股股东人数为107,241
证券之星 · 07-12
智飞生物:截至2024年7月10日,公司普通股股东人数为107,241
海通国际:给予智飞生物增持评级,目标价位46.2元
证券之星 · 07-11
海通国际:给予智飞生物增持评级,目标价位46.2元
一针不到100元?流感疫苗以价换量,智飞生物、康希诺剑指带状疱疹疫苗新蓝海
红刊财经 · 07-09
一针不到100元?流感疫苗以价换量,智飞生物、康希诺剑指带状疱疹疫苗新蓝海
智飞生物:根据相关规定,公司员工持股计划由其管理委员会负责日常管理事宜,目前该计划正常存续中
证券之星 · 07-05
智飞生物:根据相关规定,公司员工持股计划由其管理委员会负责日常管理事宜,目前该计划正常存续中
智飞生物:截至2024年6月20日,公司普通股股东人数为109310
证券之星 · 06-28
智飞生物:截至2024年6月20日,公司普通股股东人数为109310
群益证券:给予智飞生物增持评级,目标价位34.0元
证券之星 · 06-28
群益证券:给予智飞生物增持评级,目标价位34.0元
6月26日智飞生物涨5.04%,易方达创业板ETF基金重仓该股
证券之星 · 06-26
6月26日智飞生物涨5.04%,易方达创业板ETF基金重仓该股
智飞生物涨5.04%,西南证券一个月前给出“买入”评级
证券之星 · 06-26
智飞生物涨5.04%,西南证券一个月前给出“买入”评级
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬
Reuters · 06-25
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬
诸茅的落寞时刻,有多惨?
格隆汇 · 06-23
诸茅的落寞时刻,有多惨?
HPV疫苗竞争激烈?智飞生物董事长回应,私募大佬发声!
e公司 · 06-18
HPV疫苗竞争激烈?智飞生物董事长回应,私募大佬发声!
智飞生物:公司坚持“自主研发为主、合作研发为辅、投资孵化为补”的创新策略
证券之星 · 06-07
智飞生物:公司坚持“自主研发为主、合作研发为辅、投资孵化为补”的创新策略
智飞生物:截至2024年5月20日,公司普通股股东人数为112146
证券之星 · 05-31
智飞生物:截至2024年5月20日,公司普通股股东人数为112146
天风证券:给予智飞生物买入评级
证券之星 · 05-22
天风证券:给予智飞生物买入评级
比集采还狠!HPV疫苗跌到地板价,龙头企业业绩“哑火”
格隆汇 · 05-22
比集采还狠!HPV疫苗跌到地板价,龙头企业业绩“哑火”
【机构调研记录】新华基金调研智飞生物、云意电气等3只个股(附名单)
证券之星 · 05-17
【机构调研记录】新华基金调研智飞生物、云意电气等3只个股(附名单)
【机构调研记录】大成基金调研云图控股、智飞生物等4只个股(附名单)
证券之星 · 05-17
【机构调研记录】大成基金调研云图控股、智飞生物等4只个股(附名单)
【机构调研记录】中银基金调研航宇科技、智飞生物等5只个股(附名单)
证券之星 · 05-17
【机构调研记录】中银基金调研航宇科技、智飞生物等5只个股(附名单)
【机构调研记录】东方基金调研嘉泽新能、智飞生物
证券之星 · 05-17
【机构调研记录】东方基金调研嘉泽新能、智飞生物
加载更多
公司概况
公司名称:
重庆智飞生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2010-09-28
主营业务:
重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司;公司的主要产品包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品,也涵盖提供结核感染诊断、预防、治疗有效解决方案的药品。公司自成立以来,一贯注重研发与技术创新,通过十余年稳步增长的研发投入和持续深入的研发活动,形成了行业较领先的研发技术能力,并为公司可持续发展提供了技术根基。先后参与了科技部“863计划”,“现代医学技术”项目,科技部重大新药创制,国家新药创制重大专项等20余项国家级,省部级项目。
发行价格:
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":27.95,"timestamp":1721631828000,"preClose":28.33,"halted":0,"volume":17810022,"delay":0,"floatShares":1414000000,"shares":2394000000,"eps":3.1313,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.38,"latestTime":"07-22 15:00:00","open":28.33,"high":28.36,"low":27.75,"amount":499000000,"amplitude":0.0215,"askPrice":27.95,"askSize":424,"bidPrice":27.94,"bidSize":190,"shortable":0,"etf":0,"ttmEps":3.1313,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":28.33,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":31.16,"lowLimit":25.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"pbRate":2.08,"roa":"--","roe":"4.52%","epsLYR":3.3624,"committee":-0.264368,"marketValue":66906000000,"floatMarketCap":39530000000,"peRate":8.926005,"changeRate":-0.0134,"turnoverRate":0.0126,"status":1},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2452489851","title":"智飞生物(300122)7月17日主力资金净买入6411.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452489851","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452489851?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:12","pubTimestamp":1721265149,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月17日收盘,智飞生物报收于27.66元,上涨3.17%,换手率1.72%,成交量24.37万手,成交额6.7亿元。近5日资金流向一览见下表:智飞生物融资融券信息显示,融资方面,当日融资买入6501.91万元,融资偿还6312.42万元,融资净买入189.48万元,连续3日净买入累计586.28万元。融券方面,融券卖出1.13万股,融券偿还27.18万股,融券余量57.4万股,融券余额1587.55万元。智飞生物主营业务:疫苗、生物制品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800014097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2148510915.USD","BK0046","300122","BK0196","BK0077","LU1064131003.USD","LU1328615791.USD","LU1064130708.USD","BK0188"],"gpt_icon":0},{"id":"2450856365","title":"智飞生物:截至2024年7月10日,公司普通股股东人数为107,241","url":"https://stock-news.laohu8.com/highlight/detail?id=2450856365","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450856365?lang=zh_cn&edition=full","pubTime":"2024-07-12 19:02","pubTimestamp":1720782172,"startTime":"0","endTime":"0","summary":"证券之星消息,智飞生物(300122)07月12日在投资者关系平台上答复投资者关心的问题。投资者:请问截止2024年7月10日公司股东人数多少?智飞生物董秘:您好,截至2024年7月10日,公司普通股股东人数为107,241,谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200043323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0239","LU1328615791.USD","BK0077","BK0196","LU1064131003.USD","BK0188","BK0046","300122","LU2148510915.USD"],"gpt_icon":0},{"id":"2450899330","title":"海通国际:给予智飞生物增持评级,目标价位46.2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450899330","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450899330?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:45","pubTimestamp":1720694719,"startTime":"0","endTime":"0","summary":"海通国际证券集团有限公司Kehan Meng,Yilin Yuan,Wenxin Yu近期对智飞生物进行研究并发布了研究报告《三问三答,探究智飞生物经营拐点》,本报告对智飞生物给出增持评级,认为其目标价位为46.20元,当前股价为27.3元,预期上涨幅度为69.23%。2024-26年带状疱疹疫苗最低采购额分别为34.4亿元、68.8亿元、103.2亿元,3年合计采购金额206.4亿元。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级9家,增持评级4家;过去90天内机构目标均价为47.44。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100036094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"gpt_icon":0},{"id":"2450304826","title":"一针不到100元?流感疫苗以价换量,智飞生物、康希诺剑指带状疱疹疫苗新蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2450304826","media":"红刊财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450304826?lang=zh_cn&edition=full","pubTime":"2024-07-09 19:21","pubTimestamp":1720524060,"startTime":"0","endTime":"0","summary":"三价和四价流感疫苗都可有效起到预防效果,公众可自愿接种任意一种流感疫苗。不押宝流感疫苗“红海”智飞生物、康希诺等聚焦带状疱疹、流脑结合疫苗实际上,在流感疫苗中角逐的并非仅仅这四家,从2023年的签批情况来看,其中还有长春生物、百克生物、天元生物、中慧元通、赛诺菲巴斯德等公司也最终榜上有名。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709191951941f56a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709191951941f56a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688185","BK0188","LU1064131003.USD","LU1328615791.USD","06185","BK0077","BK0196","300122","BK0046","LU1064130708.USD","159646","LU2148510915.USD","BK0239"],"gpt_icon":0},{"id":"2449263615","title":"智飞生物:根据相关规定,公司员工持股计划由其管理委员会负责日常管理事宜,目前该计划正常存续中","url":"https://stock-news.laohu8.com/highlight/detail?id=2449263615","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449263615?lang=zh_cn&edition=full","pubTime":"2024-07-05 19:03","pubTimestamp":1720177395,"startTime":"0","endTime":"0","summary":"在海外,适龄男性也可以接种HPV疫苗以预防相关疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500040639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300122","BK0077","LU1064130708.USD","LU2148510915.USD","BK0196","LU1064131003.USD","BK0046","BK0188","LU1328615791.USD"],"gpt_icon":0},{"id":"2446571776","title":"智飞生物:截至2024年6月20日,公司普通股股东人数为109310","url":"https://stock-news.laohu8.com/highlight/detail?id=2446571776","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446571776?lang=zh_cn&edition=full","pubTime":"2024-06-28 18:03","pubTimestamp":1719569036,"startTime":"0","endTime":"0","summary":"证券之星消息,智飞生物06月28日在投资者关系平台上答复投资者关心的问题。投资者:作你好,诺泰生物6月19日晚间披露的业绩预告预计2024年上半年净利润为1.8亿元至2.5亿元,同比增长330.08%到497.34%。智飞生物董秘:您好,截至2024年6月20日,公司普通股股东人数为109310,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800040705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064130708.USD","300122","LU1328615791.USD","BK0188","BK0077","BK0196","LU1064131003.USD","BK0046","BK0239"],"gpt_icon":0},{"id":"2446952055","title":"群益证券:给予智飞生物增持评级,目标价位34.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446952055","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446952055?lang=zh_cn&edition=full","pubTime":"2024-06-28 16:20","pubTimestamp":1719562849,"startTime":"0","endTime":"0","summary":"群益证券(香港)有限公司王睿哲近期对智飞生物进行研究并发布了研究报告《九价HPV稳步增长,期待带状疱疹疫苗放量》,本报告对智飞生物给出增持评级,认为其目标价位为34.00元,当前股价为28.03元,预期上涨幅度为21.3%。此外,男性适应症获批后接种人群将进一步得到拓展。最新盈利预测明细如下:该股最近90天内共有12家机构给出评级,买入评级9家,增持评级3家;过去90天内机构目标均价为53.44。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800033288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","161027"],"gpt_icon":0},{"id":"2446135668","title":"6月26日智飞生物涨5.04%,易方达创业板ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446135668","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446135668?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:26","pubTimestamp":1719390367,"startTime":"0","endTime":"0","summary":"证券之星消息,6月26日智飞生物涨5.04%,收盘报28.96元,换手率1.37%,成交量19.35万手,成交额5.47亿元。重仓智飞生物的前十大公募基金请见下表:该股最近90天内共有11家机构给出评级,买入评级8家,增持评级3家;过去90天内机构目标均价为65.96。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共171家,其中持有数量最多的公募基金为易方达创业板ETF。易方达创业板ETF目前规模为550.53亿元,最新净值1.6669,较上一交易日下跌1.81%,近一年下跌22.7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600031745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","159958","BK0239","BK0188","300122","LU1064130708.USD","LU1064131003.USD","BK0196","LU2148510915.USD","BK0077","BK0046"],"gpt_icon":0},{"id":"2446946356","title":"智飞生物涨5.04%,西南证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446946356","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446946356?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:26","pubTimestamp":1719390361,"startTime":"0","endTime":"0","summary":"今日智飞生物涨5.04%,收盘报28.96元。2024年4月29日,西南证券研究员杜向阳,张殊豪发布了对智飞生物的研报《代理产品结构变化,期待带状疱疹疫苗放量》,该研报对智飞生物给出“买入”评级。研报中预计2024-2026年EPS分别为3.78元、4.44元、4.62元。维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为72.78%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中金公司的杨一正。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600031741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","300122"],"gpt_icon":0},{"id":"2446471897","title":"更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2446471897","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446471897?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:39","pubTimestamp":1719308396,"startTime":"0","endTime":"0","summary":" 路透上海6月25日 - 丹麦诺和诺德 的司美格鲁肽号称“减肥神药”,在爱美人士中走红。现在这款药物终于在中国原研专利到期前,被批准用于治疗超重和肥胖症。这意味着中国也成为继日本之后,第二个批准诺和诺德的司美格鲁肽治疗肥胖的亚洲国家。诺和诺德大中国区高管在3月表示,在中国推出的用于减肥的司美格鲁肽最开始将以自费患者为主。诺和诺德的司美格鲁肽在中国的专利将于2026年3月20日到期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","300199","BK0183","BK4534","IE0002141913.USD","LU1988902786.USD","LU1551013342.USD","LU2491049909.HKD","LU1804176565.USD","LU2148510915.USD","IE0004445239.USD","LU0882574055.USD","LU0122379950.USD","GB00BDT5M118.USD","01801","LU2237438978.USD","LU2264538146.SGD","LU1064130708.USD","LLY","LU1280957306.USD","LU1814569148.SGD","399300","LU1057294990.SGD","LU0289739699.SGD","BK4533","BK0077","BK4007","LU0109391861.USD","LU2468319806.SGD","LU0672654240.SGD","BK0070","159982","000963","BK0175","IE00B1BXHZ80.USD","BK0239","LU1551013425.SGD","BK1589","LU1023059063.AUD","300122","LU0256863811.USD","LU0417517546.SGD","LU0058720904.USD","LU0708995401.HKD","LU2491050071.SGD","IE00BJT1NW94.SGD","LU0079474960.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","03692"],"gpt_icon":0},{"id":"2445039778","title":"诸茅的落寞时刻,有多惨?","url":"https://stock-news.laohu8.com/highlight/detail?id=2445039778","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445039778?lang=zh_cn&edition=full","pubTime":"2024-06-23 16:40","pubTimestamp":1719132041,"startTime":"0","endTime":"0","summary":"腰斩不止,依旧无人问津","market":"sg","thumbnail":"https://img3.gelonghui.com/02e7b-d4ae3b25-eb39-47f4-bf23-e8b4404418ca.png?guru_height=376&guru_width=640","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/02e7b-d4ae3b25-eb39-47f4-bf23-e8b4404418ca.png?guru_height=376&guru_width=640"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/807364","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0229","BK0284","000661","BK0096","BK1161","300896","BK0060","600276","BK0012","BK1515","09939","BK0046","BK0238","BK1574","BK0057","BK0146","002507","BK0114","LU1997245177.USD","LU1997245094.SGD","LU1146622755.USD","BK0196","600763","LU1064130708.USD","BK0048","603288","BK0075","LU0979878070.USD","LU2148510915.USD","603605","BK0226","LU1064131003.USD","LU1242518857.USD","LU0405327494.USD","688076","LU1820825898.SGD","BK0183","BK0188","LU1328615791.USD","603517","BK0077","BK0236","300122","BK0251","LU0405327148.USD","LU0593848301.USD","BK0175","LU1242518931.SGD","BK0028","688363"],"gpt_icon":0},{"id":"2444803344","title":"HPV疫苗竞争激烈?智飞生物董事长回应,私募大佬发声!","url":"https://stock-news.laohu8.com/highlight/detail?id=2444803344","media":"e公司","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444803344?lang=zh_cn&edition=full","pubTime":"2024-06-18 20:49","pubTimestamp":1718714940,"startTime":"0","endTime":"0","summary":" 6月18日,A股疫苗龙头智飞生物正式召开2023年年度股东大会,上市公司董事长蒋仁生、副董事长蒋凌峰、董秘秦菲等核心高管出席,数十家机构及个人投资者参与现场会议。股东大会现场,出现了私募大佬林园的身影。 对此,蒋仁生表示,尽管HPV疫苗的市场竞争格局或在未来发生变化,但从目前来看,由默沙东研发生产的“佳达修9”疫苗仍是国内获批上市的唯一九价HPV疫苗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-06-18/doc-inazennv9115655.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-06-18/doc-inazennv9115655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","LU2148510915.USD","BK0188","BK0077","LU1328615791.USD","159646","BK0196","LU1064131003.USD","BK0046","BK0239","300122"],"gpt_icon":0},{"id":"2441513880","title":"智飞生物:公司坚持“自主研发为主、合作研发为辅、投资孵化为补”的创新策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2441513880","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441513880?lang=zh_cn&edition=full","pubTime":"2024-06-07 19:03","pubTimestamp":1717758183,"startTime":"0","endTime":"0","summary":"证券之星消息,智飞生物06月07日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700040303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0239","LU1328615791.USD","BK0077","BK0196","LU1064131003.USD","BK0188","BK0046","300122","LU2148510915.USD"],"gpt_icon":0},{"id":"2439965267","title":"智飞生物:截至2024年5月20日,公司普通股股东人数为112146","url":"https://stock-news.laohu8.com/highlight/detail?id=2439965267","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439965267?lang=zh_cn&edition=full","pubTime":"2024-05-31 18:04","pubTimestamp":1717149844,"startTime":"0","endTime":"0","summary":"证券之星消息,智飞生物05月31日在投资者关系平台上答复投资者关心的问题。截至目前,该事项在正常推进中,具体进展请持续关注公司公告。投资者:公司2023年度报告中第二页,董事长在股东致辞中称,2023年,公司年度纳税达到76.92亿元。投资者:请问截止2024年5月7日,公司持股股东人数是多少?智飞生物董秘:您好,截至2024年5月20日,公司普通股股东人数为112146,谢谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053100036331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0196","LU2148510915.USD","BK0239","300122","LU1064131003.USD","LU1328615791.USD","BK0188","BK0077","BK0046"],"gpt_icon":0},{"id":"2437676232","title":"天风证券:给予智飞生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2437676232","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437676232?lang=zh_cn&edition=full","pubTime":"2024-05-22 20:35","pubTimestamp":1716381320,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松近期对智飞生物进行研究并发布了研究报告《2023年稳健增长,重组带疱疫苗销售值得期待》,本报告对智飞生物给出买入评级,当前股价为35.08元。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有11家机构给出评级,买入评级9家,增持评级2家;过去90天内机构目标均价为58.98。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200037770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","300122"],"gpt_icon":0},{"id":"2437816472","title":"比集采还狠!HPV疫苗跌到地板价,龙头企业业绩“哑火”","url":"https://stock-news.laohu8.com/highlight/detail?id=2437816472","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437816472?lang=zh_cn&edition=full","pubTime":"2024-05-22 11:52","pubTimestamp":1716349977,"startTime":"0","endTime":"0","summary":"未来纳入免疫规划?","market":"us","thumbnail":"https://img3.gelonghui.com/134c1-8332e690-2d03-4f97-b349-570a6f919997.jpg?guru_height=852&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/134c1-8332e690-2d03-4f97-b349-570a6f919997.jpg?guru_height=852&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/747952","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["300122","LU1328615791.USD","BK0046","LU1064131003.USD","LU1064130708.USD","BK0239","BK0188","LU2148510915.USD","BK0070","BK0196","BK0077","300142","603392"],"gpt_icon":0},{"id":"2436393949","title":"【机构调研记录】新华基金调研智飞生物、云意电气等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2436393949","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436393949?lang=zh_cn&edition=full","pubTime":"2024-05-17 08:01","pubTimestamp":1715904117,"startTime":"0","endTime":"0","summary":"新华基金成立于2004年,截至目前,资产管理规模442.95亿元,排名87/203;资产管理规模283.02亿元,排名95/203;管理公募基金数73只,排名77/203;旗下公募基金经理17人,排名76/203。旗下最近一年表现最佳的公募基金产品为新华丰盈回报债券,最新单位净值为1.5,近一年增长15.39%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700011162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0264","BK0070","BK0028","LU1064130708.USD","LU2148510915.USD","BK0077","BK0188","LU1328615791.USD","BK0196","LU1064131003.USD","BK0046","300304","BK0239","300122"],"gpt_icon":0},{"id":"2436170939","title":"【机构调研记录】大成基金调研云图控股、智飞生物等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2436170939","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436170939?lang=zh_cn&edition=full","pubTime":"2024-05-17 08:01","pubTimestamp":1715904104,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及5月16日披露的机构调研信息,大成基金近期对4家上市公司进行了调研,相关名单如下:1)云图控股 个股亮点:公司主营业务是复合肥的生产和销售。;公司投资的江苏藏青新能源产业发展基金持有西藏阿里麻米措矿业开发有限公司51%股权,该公司持有西藏阿里改则县麻米错盐湖矿区锂硼矿探矿权证,目前已获得采矿权证的配号,批采矿种为锂矿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700011143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0229","BK0070","BK0027","BK0196","LU2148510915.USD","BK0239","300122","LU1064131003.USD","LU1328615791.USD","BK0188","002539","BK0077","BK0046"],"gpt_icon":0},{"id":"2436939123","title":"【机构调研记录】中银基金调研航宇科技、智飞生物等5只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2436939123","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436939123?lang=zh_cn&edition=full","pubTime":"2024-05-17 08:01","pubTimestamp":1715904079,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及5月16日披露的机构调研信息,中银基金近期对5家上市公司进行了调研,相关名单如下:1)航宇科技 个股亮点:我国国产航空发动机环形锻件的主研制单位之一;公司产品亦应用于航天火箭发动机、导弹、舰载燃机、工业燃气轮机、核电装备等高端装备领域;公司是国产商用大飞机自主发动机的环锻件核心研制单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700011111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0279","LU1064131003.USD","BK0077","LU1064130708.USD","300122","BK0196","BK0046","BK0188","LU1328615791.USD","688239","BK0239"],"gpt_icon":0},{"id":"2436939765","title":"【机构调研记录】东方基金调研嘉泽新能、智飞生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2436939765","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436939765?lang=zh_cn&edition=full","pubTime":"2024-05-17 08:01","pubTimestamp":1715904066,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为东方周期优选灵活配置混合,最新单位净值为0.77,近一年增长15.05%。旗下最新募集公募基金产品为东方中债绿色普惠主题金融债券优选指数A,类型为指数型-固收,集中认购期2024年5月9日至2024年8月8日。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240517080251877234a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240517080251877234a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2148510915.USD","BK0271","BK0188","LU1064131003.USD","601619","BK0077","LU1064130708.USD","300122","BK0196","BK0136","BK0034","BK0054","LU1328615791.USD","BK0046","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-09-28","address":"重庆市江北区庆云路1号50层","stockEarnings":[{"period":"1week","weight":0.0423},{"period":"1month","weight":-0.0334},{"period":"3month","weight":-0.3003},{"period":"6month","weight":-0.4274},{"period":"1year","weight":-0.3767},{"period":"ytd","weight":-0.5364}],"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","perCapita":"13188股","boardName":"医药制造业","registeredCapital":"239378万元","compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0118},{"period":"3month","weight":-0.0271},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":0.0025}],"survey":" 重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司;公司的主要产品包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品,也涵盖提供结核感染诊断、预防、治疗有效解决方案的药品。公司自成立以来,一贯注重研发与技术创新,通过十余年稳步增长的研发投入和持续深入的研发活动,形成了行业较领先的研发技术能力,并为公司可持续发展提供了技术根基。先后参与了科技部“863计划”,“现代医学技术”项目,科技部重大新药创制,国家新药创制重大专项等20余项国家级,省部级项目。","serverTime":1721664145531,"listedPrice":37.98,"stockholders":"107241人(较上一季度减少1.89%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}